Based on the measurements of operating efficiency obtained from Iradimed's historical financial statements, Iradimed Co may be sliding down financialy. It has an above-average probability of going through some form of financial hardship next quarter. At present, Iradimed's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 327.3 K, whereas Short and Long Term Debt Total is forecasted to decline to about 147 K. Key indicators impacting Iradimed's financial strength include:
The financial analysis of Iradimed is a critical element in measuring its lifeblood. Investors should not minimize Iradimed's ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income
20.2 Million
Iradimed
Select Account or Indicator
Market Cap
Enterprise Value
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Sales General And Administrative To Revenue
Average Inventory
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Average Receivables
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Change To Inventory
Change In Cash
Stock Based Compensation
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Capital Expenditures
Total Cash From Operating Activities
Change To Account Receivables
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Liabilities
Sale Purchase Of Stock
Investments
Change Receivables
Total Cashflows From Investing Activities
Dividends Paid
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Change To Operating Activities
Other Cashflows From Investing Activities
Change To Netincome
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Other Liab
Property Plant And Equipment Net
Current Deferred Revenue
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Other Assets
Cash And Short Term Investments
Net Receivables
Common Stock Total Equity
Common Stock Shares Outstanding
Short Term Investments
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Intangible Assets
Common Stock
Property Plant Equipment
Net Tangible Assets
Retained Earnings Total Equity
Capital Surpluse
Deferred Long Term Liab
Deferred Long Term Asset Charges
Net Invested Capital
Net Working Capital
Capital Stock
Non Current Liabilities Other
Capital Lease Obligations
Depreciation And Amortization
Interest Expense
Selling General Administrative
Selling And Marketing Expenses
Total Revenue
Gross Profit
Other Operating Expenses
Operating Income
Ebit
Research Development
Ebitda
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income Applicable To Common Shares
Income Tax Expense
Net Income From Continuing Ops
Non Operating Income Net Other
Tax Provision
Interest Income
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Iradimed Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Iradimed's financial statements are interrelated, with each one affecting the others. For example, an increase in Iradimed's assets may result in an increase in income on the income statement.
Please note, the presentation of Iradimed's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Iradimed's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Iradimed's management manipulating its earnings.
Iradimed Stock Summary
Iradimed competes with Pulmonx Corp, Orthofix Medical, Neuropace, Integer Holdings, and Glaukos Corp. IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging compatible medical devices, and related accessories and services in the United States and internationally. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida. Iradimed operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 110 people.
Comparative valuation techniques use various fundamental indicators to help in determining Iradimed's current stock value. Our valuation model uses many indicators to compare Iradimed value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Iradimed competition to find correlations between indicators driving Iradimed's intrinsic value. More Info.
Iradimed Co is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about 0.59 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Iradimed Co is roughly 1.69 . At present, Iradimed's Return On Equity is projected to slightly decrease based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Iradimed by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Iradimed Systematic Risk
Iradimed's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Iradimed volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Iradimed correlated with the market. If Beta is less than 0 Iradimed generally moves in the opposite direction as compared to the market. If Iradimed Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Iradimed is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Iradimed is generally in the same direction as the market. If Beta > 1 Iradimed moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Iradimed Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Iradimed's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Iradimed growth as a starting point in their analysis.
Price Earnings To Growth Ratio
3.23
At present, Iradimed's Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.
Iradimed March 19, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Iradimed help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Iradimed Co. We use our internally-developed statistical techniques to arrive at the intrinsic value of Iradimed Co based on widely used predictive technical indicators. In general, we focus on analyzing Iradimed Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Iradimed's daily price indicators and compare them against related drivers.
When running Iradimed's price analysis, check to measure Iradimed's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iradimed is operating at the current time. Most of Iradimed's value examination focuses on studying past and present price action to predict the probability of Iradimed's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iradimed's price. Additionally, you may evaluate how the addition of Iradimed to your portfolios can decrease your overall portfolio volatility.
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.